18F-FDG PET-CT预测可切除非小细胞肺癌新辅助PD-1阻断主要病理缓解的效率
研究纳入36例可切除非小细胞肺癌(NSCLC)初治患者,接受两周期信迪利单抗(200 mg,第1天和第22天静脉给药)后行PET-CT,评估代谢参数与主要病理缓解(MPR)的关系。MPR发生率为36.1%(13/36)。根据PERCIST,13例(36.1%)为部分代谢缓解(PMR),21例(58.3%)为代谢稳定,2例(5.6%)为代谢进展;全部PMR(ΔSULpeak% < -30.0%)肿瘤均显示MPR。18F-FDG PET-CT可预测可切除NSCLC对新辅助信迪利单抗的MPR。
要点
- 36例可切除NSCLC接受两周期信迪利单抗后,MPR发生率为36.1%(13/36)。
- PERCIST评估PMR(ΔSULpeak% < -30.0%)的肿瘤全部(100.0%)显示MPR。
- 病理缓解程度与首次扫描SULmax正相关(p=0.036),与第二次扫描代谢参数及变化百分比负相关(p<0.05)。
核心结论
- 18F-FDG PET-CT可预测可切除NSCLC对新辅助信迪利单抗的主要病理缓解(MPR)。
研究设计与样本
- 研究纳入初治可切除NSCLC(IA-IIIB期)患者,接受两周期信迪利单抗(200 mg,第1天和第22天静脉给药),第29至43天之间手术,基线和术前各行一次PET-CT。
- 共36例患者接受2剂信迪利单抗,均完成两次PET-CT,其中35例行根治性切除、1例行活检。
- 代谢参数包括SULmax、SULpeak、MTV、TLG及对应百分比变化(ΔSULmax%、ΔSULpeak%、ΔMTV%、ΔTLG%),PET反应按PERCIST分类,并与手术病理进行相关性分析。
- 试验注册号:ChiCTR-OIC-17013726。
主要发现
- 36例可评估肿瘤中MPR发生13例(36.1%,13/36)。
- 病理缓解程度与首次扫描SULmax正相关(p=0.036),与第二次扫描所有代谢参数及新辅助治疗后代谢参数百分比变化负相关(p<0.05)。
- 按PERCIST分类:部分代谢缓解(PMR)13例(36.1%,13/36),代谢稳定21例(58.3%,21/36),代谢进展(PMD)2例(5.6%,2/36)。
- 病理缓解与PERCIST分类的PET反应之间显著相关。
- 全部PMR(ΔSULpeak% < -30.0%)肿瘤均显示MPR(100.0%)。
关键数值与推荐
- MPR定义为主要病理缓解,发生率为36.1%(13/36)。
- PERCIST分类中PMR的代谢标准为ΔSULpeak% < -30.0%。
- PMR组13例(36.1%,13/36)全部显示MPR(100.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Investigate whether 18F-FDG PET-CT has the potential to predict the major pathologic response (MPR) to neoadjuvant sintilimab in resectable NSCLC patients, and the potential of sifting patients who probably benefit from immunotherapy. METHODS: Treatment-naive patients with resectable NSCLC (stage IA-IIIB) received two cycles of sintilimab (200 mg, intravenously, day 1 and 22). Surgery was performed between day 29 and 43. PET-CT was obtained at baseline and prior to surgery. The following lean body mass-corrected metabolic parameters were calculated by PET VCAR: SULmax, SULpeak, MTV, TLG, ΔSULmax%, ΔSULpeak%, ΔMTV%, ΔTLG%. PET responses were classified using PERCIST. The above metabolic information on FDG-PET was correlated with the surgical pathology. (Registration Number: ChiCTR-OIC-17013726). RESULTS: Thirty-six patients received 2 doses of sintilimab, all of whom underwent PET-CT twice and had radical resection (35) or biopsy (1). MPR occurred in 13 of 36 resected tumors (36.1%, 13/36). The degree of pathological regression was positively correlated with SULmax (p = 0.036) of scan-1, and was negatively correlated with all metabolic parameters of scan-2, and the percentage changes of the metabolic parameters after neoadjuvant therapy (p < 0.05). According to PERCIST, 13 patients (36.1%, 13/36) showed partial metabolic response (PMR), 21 (58.3%, 21/36) had stable metabolic disease, and 2 (5.6%, 2/36) had progressive metabolic disease (PMD). There was a significant correlation between the pathological response and the PET responses which were classified using PERCIST. All (100.0%) the PMR (ΔSULpeak% < - 30.0%) tumors showed MPR. CONCLUSIONS: 18F-FDG PET-CT can predict MPR to neoadjuvant sintilimab in resectable non-small cell lung cancer.
引用
- Tao X, Li N, Wu N, et al. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32043180. doi:10.1007/s00259-020-04711-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。